In a randomized clinical trial, researchers determined whether brexpiprazole is an efficacious, safe, and well-tolerated treatment for agitation in patients with Alzheimer dementia. Brexpiprazole, 2 ...
According to the letter, the application could not be approved due to lack of substantial efficacy from the submitted studies. The Food and Drug Administration (FDA) has issued a Complete Response ...
Alembic has received permission from the Food and Drug Administration for brexpiprazole tablets, which is the generic of Otsuka’s Rexulti. Brexpiprazole is an atypical antipsychotic used as an ...
Questions have been raised after the US Food and Drug Administration (FDA) recently fast-tracked its approval of brexpiprazole (Rexulti), an antipsychotic for treating agitation in dementia patients, ...
Whether brexpiprazole (Rexulti) is effective as adjunctive treatment for post-traumatic stress disorder (PTSD) will be debated at an FDA advisory committee meeting on Friday. The atypical ...
A combination of brexpiprazole (Rexulti) and sertraline improved post-traumatic stress disorder (PTSD) symptoms more than sertraline alone, a phase III trial found. The primary endpoint was the change ...
An article in The BMJ is sounding the alarm that the US Food and Drug Administration fast-tracked approval for the dementia drug Rexulti (brexpiprazole) — even though trials show the drug is harmful.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results